Promise of Bispecific Antibodies in MM
Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers explains the promise of bispecific antibodies in multiple myeloma (MM) treatment for patients.
Author: obr
Added: 07/01/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts